Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tumorigenicity decrease in Bcl-xL deficient MDCK cells ensuring the safety for influenza vaccine production.

PloS one·2024

Same author

Production, Passaging Stability, and Histological Analysis of Madin-Darby Canine Kidney Cells Cultured in a Low-Serum Medium.

Vaccines·2024

Same author

Correction: Nian et al. Coping Strategies for Pertussis Resurgence. <i>Vaccines</i> 2023, <i>11</i>, 889.

Vaccines·2024

Same author

Publisher Correction: Rational design of a 'two-in-one' immunogen DAM drives potent immune response against mpox virus.

Nature immunology·2024

Same author

Rational design of a 'two-in-one' immunogen DAM drives potent immune response against mpox virus.

Nature immunology·2024

Same author

30-Year Development of Inactivated Virus Vaccine in China.

Pharmaceutics·2023

Search research articles

Related Experiment Video

Updated: May 11, 2026

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System

Published on: November 6, 2013

Enhanced Downstream Processing for a Cell-Based Avian Influenza (H5N1) Vaccine.

Fang Li^1,2,3,4, Bo Liu^1,2,3,4, Yu Xiong^1,2,3,4

¹National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.

|February 24, 2024

Summary

This study presents an improved downstream process for H5N1 avian influenza vaccines, enhancing safety by reducing host cell DNA and proteins. The method ensures antigen integrity for effective cell-based vaccine production.

Keywords:

CaptoTM Core 700 H5N1 HPAIV MDCK cells downstream purification process hydrophobic chromatography

More Related Videos

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

Preparation of Pseudo-Typed H5 Avian Influenza Viruses with Calcium Phosphate Transfection Method and Measurement of Antibody Neutralizing Activity

Preparation of Pseudo-Typed H5 Avian Influenza Viruses with Calcium Phosphate Transfection Method and Measurement of Antibody Neutralizing Activity

Published on: November 22, 2021

Related Experiment Videos

Last Updated: May 11, 2026

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System

Published on: November 6, 2013

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

Preparation of Pseudo-Typed H5 Avian Influenza Viruses with Calcium Phosphate Transfection Method and Measurement of Antibody Neutralizing Activity

Preparation of Pseudo-Typed H5 Avian Influenza Viruses with Calcium Phosphate Transfection Method and Measurement of Antibody Neutralizing Activity

Published on: November 22, 2021

Area of Science:

Virology
Biotechnology
Vaccine Development

Background:

H5N1 highly pathogenic avian influenza virus (HPAIV) poses a significant global health threat.
Existing H5N1 HPAIV vaccines face limited approval due to safety concerns, particularly MDCK cell tumorigenicity.
Minimizing residual DNA and host cell proteins (HCP) is crucial for enhancing vaccine safety.

Purpose of the Study:

To develop an improved downstream processing method for cell-based H5N1 HPAIV vaccines.
To enhance vaccine safety by significantly reducing residual DNA and HCP levels.
To ensure the integrity and efficacy of the H5N1 HPAIV antigen.

Main Methods:

A two-step chromatographic process was developed for vaccine purification.
Capto™ Core 700, a multimodal resin, was utilized for polishing.
Hydrophobic-interaction chromatography (HIC) with polypropylene glycol facilitated virus particle capture.

Main Results:

Virus recovery achieved 68.16% following the two-step chromatographic process.
Host cell protein (HCP) levels were reduced to 2112.60 ng/mL.
Residual DNA levels were reduced to 6.4 ng/mL.
Western blot, HPLC, and TEM confirmed antigen presence, spherical shape, and appropriate particle size.

Conclusions:

The developed two-step downstream process is effective in reducing DNA and HCP in cell-based H5N1 HPAIV vaccines.
This method ensures the quality and safety of the H5N1 HPAIV antigen.
The process shows potential as an efficient and cost-effective platform for cell-based influenza vaccines.